Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks

Lynovex, a reformulated version of a molecule which has been around for decades for a rare metabolic disease, has just succeeded in a Phase IIb study to treat exacerbations in cystic fibrosis. The mutation-agnostic therapy could improve on current treatments for breakthrough exacerbations, and reduce the associated long-term damaged.

Dog
Full speed ahead for Lynovex after Phase IIb • Source: Shutterstock

NovaBiotics Ltd. is making plans to progress its oral treatment for cystic fibrosis exacerbations into Phase III by early next year, after reporting positive Phase IIb results. The company is hopeful that it will be able to file for approval of Lynovex (cysteamine) in 2020 should Phase III studies prove positive. It sees its therapy for acute use as complementary to other approaches to treating and managing CF.

CEO Deborah O'Neil told Scrip that the treatment had the potential to provide better control of CF exacerbations than current...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category